PDCD1 and neoplasm: At the same time, the increase in the frequency and activation of NK cells can enhance the response to anti-PD-1 therapy, and the rescue of NK cell activity can enhance the anti-tumor activity of adaptive T cells, thus increasing the overall survival rate of patients with multiple types of cancer (44).